IMPACT: Healthcare resource use data and associated costs for single-inhaler triple therapy versus dual therapies in Spain

Abstract

Introduction: The IMPACT study (NCT02164513) demonstrated the clinical benefit of single-inhaler triple therapy (fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI)) versus dual therapy with FF/VI and UMEC/VI in patients with moderate/severe COPD.

Objective: To evaluate differences in healthcare resource use (HRU) and associated costs between FF/UMEC/VI, FF/VI, and UMEC/VI, among patients with COPD using data from the IMPACT trial, from a Spanish National Healthcare System (NHS) perspective.

Methods: This study is a post-hoc analysis of COPD-related, self-reported HRU data, collected in the 52-week IMPACT study during the on-treatment period, including unscheduled visits to a physician office/clinic, urgent care/outpatient center, emergency department, home care, and hospital days (general ward and intensive care unit). A Bayesian approach was applied to estimate marginal per patient per year (PPPY) HRU rates, accounting for partially available information. Average unit costs from official tariffs of Spanish Autonomous Regions were applied to the HRU rates to generate cost estimates (2019, EUR).

Results: Treatment with FF/UMEC/VI was associated with lower rates of HRU compared with either FF/VI or UMEC/VI. Total HRU-related costs PPPY for FF/UMEC/VI, FF/VI, and UMEC/VI were €2004 (95% CrI: €1811, 2226), €2291 (€2067, 2546), and €2388 (€2114, 2597), respectively. Incremental HRU costs for FF/UMEC/VI were -€287 vs FF/VI and -€334 vs UMEC/VI.

Conclusions: In patients with COPD, treatment with FF/UMEC/VI is associated with lower HRU-related costs when compared with FF/VI and UMEC/VI from the Spanish NHS perspective.

Funding: GSK (HO-18-16283)